All In Biotech

Drug Trial Radar · NCT07063576

Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms

Effect of Baclofen as an Add on Therapy in Management of Patients With Gastroesophageal Reflux Disease Symptoms

Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Adnan Imtiaj RahulAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the effect of using baclofen along with conventional treatment in improving GERD symptoms. It will also assess the safety of drug baclofen by recording the patient reported adverse events. The main questions it aims to answer are : Does drug baclofen along with conventional treatment has any effect on patients with GERD symptoms? What medical problems do participants have when taking drug baclofen? Researcher will compare drug baclofen along with conventional treatment to a control group taking placebo along with conventional treatment. Participants will: Take drug baclofen 10 milligrams or placebo three times daily along with conventional treatment for 4 weeks. They will visit the hospital after 4 weeks. Their symptoms will be assessed via validated GERD Q questionnaire at baseline and after 4 weeks. Additionally, patient reported adverse events will be documented.

Conditions

  • GERD - PPI Non-responders

Interventions

  • Baclofen 10mgDrug

    Tablet baclofen 10mg three times daily along with conventional treatment

  • PlaceboDrug

    Tablet placebo three times daily along with conventional treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of GERD symptomsTime frame: At baseline before randomization and at week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dhaka Medical College

    Dhaka, Bangladesh · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.